These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35608267)

  • 1. Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness.
    Morrell ED; Bhatraju PK; Sathe NA; Lawson J; Mabrey L; Holton SE; Presnell SR; Wiedeman A; Acosta-Vega C; Mitchem MA; Liu T; Chai XY; Sahi S; Brager C; Orlov M; Sakr SS; Sader A; Lum DM; Koetje N; Garay A; Barnes E; Cromer G; Bray MK; Pipavath S; Fink SL; Evans L; Long SA; West TE; Wurfel MM; Mikacenic C
    Am J Physiol Lung Cell Mol Physiol; 2022 Jul; 323(1):L14-L26. PubMed ID: 35608267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
    Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
    Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness.
    Tincati C; Cannizzo ES; Giacomelli M; Badolato R; d'Arminio Monforte A; Marchetti G
    Front Immunol; 2020; 11():580987. PubMed ID: 33193384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype.
    Trombetta AC; Farias GB; Gomes AMC; Godinho-Santos A; Rosmaninho P; Conceição CM; Laia J; Santos DF; Almeida ARM; Mota C; Gomes A; Serrano M; Veldhoen M; Sousa AE; Fernandes SM
    Front Immunol; 2021; 12():691725. PubMed ID: 34248984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.
    Bermejo-Martin JF; González-Rivera M; Almansa R; Micheloud D; Tedim AP; Domínguez-Gil M; Resino S; Martín-Fernández M; Ryan Murua P; Pérez-García F; Tamayo L; Lopez-Izquierdo R; Bustamante E; Aldecoa C; Gómez JM; Rico-Feijoo J; Orduña A; Méndez R; Fernández Natal I; Megías G; González-Estecha M; Carriedo D; Doncel C; Jorge N; Ortega A; de la Fuente A; Del Campo F; Fernández-Ratero JA; Trapiello W; González-Jiménez P; Ruiz G; Kelvin AA; Ostadgavahi AT; Oneizat R; Ruiz LM; Miguéns I; Gargallo E; Muñoz I; Pelegrin S; Martín S; García Olivares P; Cedeño JA; Ruiz Albi T; Puertas C; Berezo JÁ; Renedo G; Herrán R; Bustamante-Munguira J; Enríquez P; Cicuendez R; Blanco J; Abadia J; Gómez Barquero J; Mamolar N; Blanca-López N; Valdivia LJ; Fernández Caso B; Mantecón MÁ; Motos A; Fernandez-Barat L; Ferrer R; Barbé F; Torres A; Menéndez R; Eiros JM; Kelvin DJ
    Crit Care; 2020 Dec; 24(1):691. PubMed ID: 33317616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
    Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
    Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way.
    Cao Z; Wang J; Liu X; Liu Y; Li F; Liu M; Chiu S; Jin X
    mBio; 2024 Jun; 15(6):e0090524. PubMed ID: 38727220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response.
    Loretelli C; Abdelsalam A; D'Addio F; Ben Nasr M; Assi E; Usuelli V; Maestroni A; Seelam AJ; Ippolito E; Di Maggio S; Loreggian L; Radovanovic D; Vanetti C; Yang J; El Essawy B; Rossi A; Pastore I; Montefusco L; Lunati ME; Bolla AM; Biasin M; Antinori S; Santus P; Riva A; Zuccotti GV; Galli M; Rusconi S; Fiorina P
    JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34784300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive immunity to SARS-CoV-2 infection: A systematic review.
    Silva MJA; Ribeiro LR; Lima KVB; Lima LNGC
    Front Immunol; 2022; 13():1001198. PubMed ID: 36300105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early versus late tracheostomy in critically ill COVID-19 patients.
    Szafran A; Dahms K; Ansems K; Skoetz N; Monsef I; Breuer T; Benstoem C
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015532. PubMed ID: 37982427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India.
    Venkataraman A; Kumar NP; Hanna LE; Putlibai S; Karthick M; Rajamanikam A; Sadasivam K; Sundaram B; Babu S
    EBioMedicine; 2021 Apr; 66():103317. PubMed ID: 33813138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study.
    Torres-Ruiz J; Lomelín-Gascón J; Vargas-Castro AS; Lira-Luna J; Pérez-Fragoso A; Tapia-Conyer R; Nuñez-Aguirre M; Alcalá-Carmona B; Absalón-Aguilar A; Maravillas-Montero JL; Mejía-Domínguez NR; Núñez-Álvarez C; Rull-Gabayet M; Llorente L; Romero-Ramírez S; Sosa-Hernández VA; Cervantes-Díaz R; Juárez-Vega G; Meza-Sánchez DE; Martínez-Juárez LA; Morales-Juárez L; López-López LN; Negrete-Trujillo JA; Falcón-Lezama JA; Valdez-Vázquez RR; Gallardo-Rincón H; Gómez-Martín D
    Front Immunol; 2022; 13():943563. PubMed ID: 36045688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Dysregulation in COVID-19 Patients.
    Sabbatino F; Conti V; Franci G; Sellitto C; Manzo V; Pagliano P; De Bellis E; Masullo A; Salzano FA; Caputo A; Peluso I; Zeppa P; Scognamiglio G; Greco G; Zannella C; Ciccarelli M; Cicala C; Vecchione C; Filippelli A; Pepe S
    Front Immunol; 2021; 12():695242. PubMed ID: 34163490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology.
    Karaba AH; Zhou W; Hsieh LL; Figueroa A; Massaccesi G; Rothman RE; Fenstermacher KZJ; Sauer L; Shaw-Saliba K; Blair PW; Robinson ML; Leung S; Wesson R; Alachkar N; El-Diwany R; Ji H; Cox AL
    Clin Infect Dis; 2022 Jan; 74(2):254-262. PubMed ID: 34013339
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Viurcos-Sanabria R; Manjarrez-Reyna AN; Solleiro-Villavicencio H; Rizo-Téllez SA; Méndez-García LA; Viurcos-Sanabria V; González-Sanabria J; Arroyo-Valerio A; Carrillo-Ruíz JD; González-Chávez A; León-Pedroza JI; Flores-Mejía R; Rodríguez-Cortés O; Escobedo G
    Front Immunol; 2022; 13():897995. PubMed ID: 35860236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.
    Remy KE; Mazer M; Striker DA; Ellebedy AH; Walton AH; Unsinger J; Blood TM; Mudd PA; Yi DJ; Mannion DA; Osborne DF; Martin RS; Anand NJ; Bosanquet JP; Blood J; Drewry AM; Caldwell CC; Turnbull IR; Brakenridge SC; Moldwawer LL; Hotchkiss RS
    JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32687484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.